PTJ
CLDX icon

Paul Tudor Jones’s Celldex Therapeutics CLDX Stock Holding History

Paul Tudor Jones’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,393
Closed -$1.12M – 3640
2026
Q1 		$1.12M Buy
+35,393
New +$965K ﹤0.01% 2282
2025
Q4 		– Sell
-31,618
Closed -$818K – 3543
2025
Q3 		$818K Buy
+31,618
New +$733K ﹤0.01% 2400
2025
Q2 		– Sell
-35,141
Closed -$638K – 3314
2025
Q1 		$638K Buy
35,141
+2,596
+8% +$58K ﹤0.01% 2125
2024
Q4 		$822K Buy
+32,545
New +$884K ﹤0.01% 1869
2024
Q2 		– Sell
-67,384
Closed -$2.83M – 2369
2024
Q1 		$2.83M Buy
67,384
+52,842
+363% +$2.17M 0.02% 857
2023
Q4 		$577K Sell
14,542
-7,496
-34% -$220K ﹤0.01% 1723
2023
Q3 		$606K Sell
22,038
-1,637
-7% -$51.3K 0.01% 1579
2023
Q2 		$803K Sell
23,675
-3,600
-13% -$121K 0.01% 1431
2023
Q1 		$981K Buy
+27,275
New +$1.18M 0.02% 1216
2019
Q1 		– Sell
-4,363
Closed -$13K – 1114
2018
Q4 		$13K Hold
4,363
– – ﹤0.01% 977
2018
Q3 		$30K Hold
4,363
– – ﹤0.01% 1055
2018
Q2 		$33K Sell
4,363
-1,404
-24% -$18.8K ﹤0.01% 1010
2018
Q1 		$202K Sell
5,767
-1,088
-16% -$42.2K 0.01% 869
2017
Q4 		$292K Buy
6,855
+2,878
+72% +$123K 0.01% 811
2017
Q3 		$171K Buy
3,977
+3,010
+311% +$113K ﹤0.01% 981
2017
Q2 		$36K Buy
+967
New +$42.8K ﹤0.01% 987
2017
Q1 		– Sell
-3,187
Closed -$169K – 1389
2016
Q4 		$169K Buy
3,187
+2,293
+256% +$130K ﹤0.01% 1251
2016
Q3 		$54K Sell
894
-115
-11% -$7.16K ﹤0.01% 1369
2016
Q2 		$66K Sell
1,009
-8,287
-89% -$526K ﹤0.01% 1541
2016
Q1 		$527K Buy
9,296
+8,239
+779% +$927K 0.01% 909
2015
Q4 		$249K Buy
+1,057
New +$230K 0.01% 1323
2015
Q2 		– Sell
-1,887
Closed -$789K – 1512
2015
Q1 		$789K Buy
+1,887
New +$675K 0.03% 482

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's CLDX Position: Q2 2026 in Review

Paul Tudor Jones sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 35,393 shares — an estimated $1.12M sold.

Paul Tudor Jones first reported a position in CLDX in Q1 2015 and held it in 22 quarters. The position peaked at $2.83M in Q1 2024. 252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Paul Tudor Jones reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 35,393 Celldex Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Paul Tudor Jones first reported a position in Celldex Therapeutics in Q1 2015 and held it in 22 quarters.
  • Paul Tudor Jones's Celldex Therapeutics position peaked at $2.83M in Q1 2024.
  • 252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.